Biontech Se
- All
- News
- Videos
-
Pfizer Shots, Prior Infection May Protect Better vs Omicron: Scientists
A two-dose course of Pfizer Inc. and BioNTech SE's Covid-19 shot as well as a previous infection with the disease may give stronger protection against the omicron variant, scientists from the Africa Health Research Institute in South Africa said.
-
On Omicron vs Vaccines, New Grounds For Cautious Optimism
The earliest studies on omicron are in and the glimpse they're providing is cautiously optimistic: while vaccines like the one made by Pfizer Inc. and BioNTech SE may be less powerful against the new variant, protection can be fortified with boosters
-
Omicron Scare: Pfizer Says Third Dose Key To Fight Spread
Pfizer Inc. and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world and may lead to use of new strain-spec
-
For Omicron, Third Dose Of Covid Shot May Be Needed: Pfizer
Pfizer and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world.
-
Shots Should Protect From Worst Of Omicron, Says Big Vaccine-Maker
The current generation of Covid-19 vaccines probably will still protect against severe disease in people infected by the omicron variant, BioNTech SE Chief Executive Officer Ugur Sahin said.
-
BioNTech Is Working On An 'Omicron' Version Of Its Covid Shot
BioNTech SE is working to adapt its Covid-19 vaccine to address the 'Omicron' variant and expects to have a new version ready within 100 days if necessary.
-
What To Know About COVID-19 Vaccine For US Children
The US Food and Drug Administration is considering authorizing a COVID-19 vaccine for children aged 5 to 11. The vaccine from Pfizer Inc and BioNTech SE has been available in the United States to kids aged 12 to 15 since May.
-
Covid Protection Wanes Months After Second Shot, Booster Needed: Study
Immunity provided by the Covid-19 vaccine from partners Pfizer Inc. and BioNTech SE weakens significantly within months, with men having less protection than women, according to research that supports the use of booster doses.
-
Moderna's Shot Creates Twice As Many Antibodies As Pfizer, Study Shows
Moderna Inc.'s Covid vaccine generated more than double the antibodies of a similar shot made by Pfizer Inc. and BioNTech SE in research directly comparing immune responses to the inoculations.
-
Pfizer Submits Initial Data For Covid Vaccine Booster Authorization
Pfizer Inc and its German partner BioNTech SE have submitted to U.S. regulators the initial data from an early-stage trial toward seeking authorization of a booster dose of their COVID-19 vaccine, the drugmakers said on Monday.
-
Pfizer Shots, Prior Infection May Protect Better vs Omicron: Scientists
A two-dose course of Pfizer Inc. and BioNTech SE's Covid-19 shot as well as a previous infection with the disease may give stronger protection against the omicron variant, scientists from the Africa Health Research Institute in South Africa said.
-
On Omicron vs Vaccines, New Grounds For Cautious Optimism
The earliest studies on omicron are in and the glimpse they're providing is cautiously optimistic: while vaccines like the one made by Pfizer Inc. and BioNTech SE may be less powerful against the new variant, protection can be fortified with boosters
-
Omicron Scare: Pfizer Says Third Dose Key To Fight Spread
Pfizer Inc. and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world and may lead to use of new strain-spec
-
For Omicron, Third Dose Of Covid Shot May Be Needed: Pfizer
Pfizer and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world.
-
Shots Should Protect From Worst Of Omicron, Says Big Vaccine-Maker
The current generation of Covid-19 vaccines probably will still protect against severe disease in people infected by the omicron variant, BioNTech SE Chief Executive Officer Ugur Sahin said.
-
BioNTech Is Working On An 'Omicron' Version Of Its Covid Shot
BioNTech SE is working to adapt its Covid-19 vaccine to address the 'Omicron' variant and expects to have a new version ready within 100 days if necessary.
-
What To Know About COVID-19 Vaccine For US Children
The US Food and Drug Administration is considering authorizing a COVID-19 vaccine for children aged 5 to 11. The vaccine from Pfizer Inc and BioNTech SE has been available in the United States to kids aged 12 to 15 since May.
-
Covid Protection Wanes Months After Second Shot, Booster Needed: Study
Immunity provided by the Covid-19 vaccine from partners Pfizer Inc. and BioNTech SE weakens significantly within months, with men having less protection than women, according to research that supports the use of booster doses.
-
Moderna's Shot Creates Twice As Many Antibodies As Pfizer, Study Shows
Moderna Inc.'s Covid vaccine generated more than double the antibodies of a similar shot made by Pfizer Inc. and BioNTech SE in research directly comparing immune responses to the inoculations.
-
Pfizer Submits Initial Data For Covid Vaccine Booster Authorization
Pfizer Inc and its German partner BioNTech SE have submitted to U.S. regulators the initial data from an early-stage trial toward seeking authorization of a booster dose of their COVID-19 vaccine, the drugmakers said on Monday.
